Latanoprost E Timololo Teva Italia

Timolol maleate and Latanoprost, the active ingredients in Latanoprost E Timololo Teva Italia, are a beta‑adrenergic antagonist and a prostaglandin F2α analog presented as eye drops for ocular (topical) use. They treat open‑angle glaucoma and ocular hypertension in adults.

GNH USA supplies Latanoprost E Timololo Teva Italia as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Latanoprost E Timololo Teva Italia is indicated for conditions affecting intra‑ocular pressure within the glaucoma disease family. - Open‑angle glaucoma: lowers intra‑ocular pressure to help prevent optic‑nerve damage. - Ocular hypertension: reduces eye pressure to lower the risk of progression to glaucoma.

Common Side Effects: - Eye irritation or burning sensation. - Blurred vision shortly after instillation. - Redness of the conjunctiva. - Itching or mild allergic reaction. - Dry eye sensation. - Increased iris pigmentation or eyelash growth.

Serious or Rare Side Effects: - Severe allergic reaction such as anaphylaxis. - Sudden loss of vision or acute eye pain. - Worsening of glaucoma despite therapy. - Systemic beta‑blocker effects (bradycardia, bronchospasm).

Before using Latanoprost E Timololo Teva Italia, consider the following precautions. - Contraindications: avoid in patients with known hypersensitivity to timolol or latanoprost. - Cardiovascular risk: assess for asthma, COPD, bradycardia, or heart block before initiating therapy. - Monitor intra‑ocular pressure regularly to ensure therapeutic response. - Contact lens wearers: remove lenses before instillation and wait at least 15 minutes before reinserting. - Pregnancy and lactation: safety not established; use only if benefit outweighs risk. - Store at room temperature: keep bottle tightly closed, protect from light and moisture.

Latanoprost E Timololo Teva Italia may interact with other medicines as follows. Major Interactions (Avoid): - Systemic non‑selective beta‑blockers (e.g., propranolol): additive bradycardia or hypotension. - Other ocular beta‑blocker preparations: risk of excessive intra‑ocular pressure reduction. - Sympathomimetic agents (e.g., epinephrine eye drops): antagonistic effect on timolol. Moderate Interactions (Monitor Closely): - Carbonic anhydrase inhibitor eye drops: potential additive pressure‑lowering effect. - Topical corticosteroids: may increase risk of ocular side effects such as pigmentation changes. - Anticholinergic eye drops: monitor for dry eye or irritation.